News

Ophthalmology Times4d
SpyGlass Pharma secures $75 million in Series D financing round
SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...
Pharmaceutical Technology on MSN4d
SpyGlass Pharma secures $75m for ophthalmic drug delivery platform
SpyGlass Pharma has closed a Series D funding round, raising $75m to advance the company's drug delivery platform to offer ...
Morningstar6d
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ...
WGNO1mon
SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform
April 24, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced that 18-month data from the first-in-human study of the SpyGlass Drug ...
WGNO6mon
SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension
Nov. 19, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced completion of enrollment in its Phase I/II, randomized, multi-center ...
Drug Delivery Business6d
SpyGlass Pharma raises $75M for drug delivery platform
SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform.